Jazz Pharmaceuticals (JAZZ) Higher After Positive Analyst Ratings
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $250.41 -1.5%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 29
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 29
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is seeing interest this morning on a couple positive ratings.
Barclays upgraded Jazz from Equalweight to Overweight and increased their price target from $12 to $15. In addition, Capstone Research initiated coverage on Jazz with a Buy rating and $11.50 price target.
Shares of JAZZ last traded at $8.50, up 5.5 percent.
Real-Time Market Moving News and Intelligence –Sign-Up Free Today
http://www.streetinsider.com/premium_content.php
Barclays upgraded Jazz from Equalweight to Overweight and increased their price target from $12 to $15. In addition, Capstone Research initiated coverage on Jazz with a Buy rating and $11.50 price target.
Shares of JAZZ last traded at $8.50, up 5.5 percent.
Real-Time Market Moving News and Intelligence –Sign-Up Free Today
http://www.streetinsider.com/premium_content.php
You May Also Be Interested In
- Bernstein SocGen Group Upgrades Sona BLW Precision (SONACOMS:IN) to Outperform
- Adani Green Energy (ADANIGR:IN) PT Raised to INR1,650 at Investec
- Tesla to report earnings today: Analysts flag key themes that could drive the stock
Create E-mail Alert Related Categories
Insiders' Blog, New Coverage, Trader Talk, UpgradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
